-

04:32:45 PM

TARA Stock News

TARA - Protara Therapeutics Inc

10/12/21 7:00 AM

Nasdaq : TARA

Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative

RHEA-AI

neutral

09/17/21 4:05 PM

Nasdaq : TARA

conferences

Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the Oppenheimer Fall

RHEA-AI

neutral

09/13/21 7:00 AM

Nasdaq : TARA

Protara Therapeutics Announces Results from a Retrospective Study Evaluating the Prevalence of Cholestasis in Patients Dependent on Parenteral Nutrition

-Study found that approximately 30% of patients who are dependent on parenteral nutrition have cholestasis- -Results support significant unmet medical need in patients dependent on parenteral nutrition who have intestinal failure associated liver disease- NEW YORK, Sept. 13, 2021

RHEA-AI

neutral

09/07/21 8:00 AM

Nasdaq : TARA

conferences

Protara Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the H.C. Wainwright 23rd

RHEA-AI

neutral

08/05/21 8:00 AM

Nasdaq : TARA

earnings

Protara Therapeutics Announces Second Quarter 2021 Financial Results and Business Overview

- Successfully Completed IND-Enabling Studies for TARA-002 in Patients with NMIBC; On Track to Initiate Phase 1 Trial by Year-End - - TARA-002 GMP Scale up and Comparability Ongoing and Expected to be Completed by Year-End - - Company Plans to Engage with FDA to Determine Clinical Trial Design for

RHEA-AI

positive

07/07/21 8:00 AM

Nasdaq : TARA

conferences

Protara Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the Ladenburg Thalmann

RHEA-AI

neutral

06/10/21 8:00 AM

Nasdaq : TARA

management

Protara Therapeutics Announces Appointment of Jane Huang, M.D. to Board of Directors

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Jane Huang, M.D. to its Board of

RHEA-AI

neutral

05/13/21 8:00 AM

Nasdaq : TARA

conferences

Protara Therapeutics to Participate in Upcoming Virtual Investor Conferences

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at two upcoming virtual

RHEA-AI

neutral

05/06/21 7:30 AM

Nasdaq : TARA

earnings

Protara Therapeutics Announces First Quarter 2021 Financial Results and Business Overview

- On Track to File IND and Initiate Phase 1 Trial of TARA-002 in Patients with NMIBC by Year-End - - On Track to Complete TARA-002 GMP Scale up and Comparability in 2H, 2021 - - Plan to Engage with FDA and Initiate Clinical Study of TARA-002 in Lymphatic Malformations - - Strong Cash, Cash

RHEA-AI

neutral

04/23/21 7:00 AM

Nasdaq : TARA

Protara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic Malformations

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for

RHEA-AI

very positive

TARA Data:

IndustryBiological Product (except Diagnostic) Manufacturing
Websiteprotaratx.com/
CeoJesse Shefferman
Security nameProtara Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2836
Tags
- Health Technology
- Biotechnology
- Pharmaceuticals: Major
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Address1 Little West 12Th Street
StateNew York
CityNew York
Zip10014
CountryUS
Phone16468440337

TARA Description:

Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara's portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease.